2022 BRN Discussion, page-7801

have posted in my biotech holdings as well, but have posted the same around the use of AI in medicine, and the huge benefits of same.....
as said not promoing the company but later today will look at what they all about and whose or what AI they are using,

"""
about a year ago with FDA looking for a new head, woodcock mentioned about a new way for the FDA to change, and around the very expensive and long long timeframes... there is, and must be a better way to achieve prodcut to market for pharmas.
i have posted before about the use of AI in modeling re trials etc.
not promoing the company mentioned but more about the AI used.

"

Machine learning, AI in drug development

Recursion Pharmaceuticals is a NASDAQ-listed firm, with a market cap of around US$1 billion, that is using data to help improve the above systems and processes. Dvornak described it as trying to build an “atlas of human biology.”

The traditional methods of gathering data in the pharmaceuticals industry are via experiments, involving highly-skilled, specialised scientists in slow, precise, and painstaking processes. “A lot of money is spent to produce only a small amount of data output, it’s prohibitively expensive,” said Dvornak.

But using artificial intelligence and robotics technology, Recursion enables some 2.5 million experiments to be conducted weekly, enabling the creation of a large database far more cheaply than was previously possible.

Recursion’s technology is able to create up to 13 petabytes of data – which amounts to around 13.6 trillion A4 pages of printed text.

“Thanks to advances in machine learning and neural networks, computers can translate those pages and formulate models of human biology. As more data becomes available, the machine’s understanding of human biology will expand,” said Dvornak.

This enables quicker estimations of the probability of failure for new drugs, to help them “fail earlier,” limiting the resources and time expended.